Why the New DAC Modality Is Gaining Attention

Conventional Antibody‑Drug Conjugates (ADCs) and Targeted Protein Degradation (TPD) therapeutics have each led the market with their ability to target cancer cells and their potent protein‑removal capabilities, respectively, but they have encountered barriers related to toxicity and limited cellular permeability. Degrader‑Antibody Conjugates (DAC), which combine the advantages of both technologies, constitute an innovative platform that uses the antibody’s precise targeting ability to deliver a degrader payload into cells. Because the degrader payload acts catalytically to fully eliminate the target protein, it can achieve superior and durable therapeutic effects at much lower concentrations than conventional ADCs. The industry is accelerating DAC development as a next‑generation standard therapy to address the unmet medical needs of hard‑to‑treat diseases.

What the $1 Billion Roche‑C4 Therapeutics Partnership Signifies

Swiss pharmaceutical company Roche (RHHBY) expanded its partnership with U.S. C4 Therapeutics (CCCC) in April 2026, committing an upfront payment of $20 million and milestone payments exceeding $1 billion for DAC development. Under the agreement, C4 Therapeutics will use its TORPEDO platform to design the payloads, while Roche will assume responsibility for clinical development and commercialization. This follows the termination in November 2025 of a prior $610 million deal between Merck (MRK) and C4 Therapeutics, reaffirming the platform’s value. Large pharmaceutical companies are accelerating the adoption of DAC platform technology to secure exclusive Oncology targets.

Orum Therapeutics Leads the Front‑Runner Group’s Technical Advances

South Korea’s Orum Therapeutics has placed its acute myeloid leukemia (AML) candidate ORM‑6151 (BMS‑986497), transferred to Bristol Myers Squibb (BMY) for $180 million, into Phase 1, positioning the company at the forefront. In July 2024, it also secured a $945 million licensing agreement for its TPD² platform technology with Vertex Pharmaceuticals (VRTX). Furthermore, in December 2025 the company raised approximately $100 million to accelerate clinical development of its lead pipeline candidate ORM‑1153 and to expand the platform. This reflects an aggressive financing strategy aimed at overcoming toxicity issues in its prior pipeline and demonstrating the clinical viability of the new platform.

Pfizer, Nurix, and Prelude Shape the Emerging Competitive Landscape

Pfizer (PFE) reinforced its Oncology pipeline by successfully inheriting the DAC co‑research partnership with Nurix Therapeutics (NRIX) when it acquired Seagen. Nurix previously signed a deal with Seagen that included a $60 million upfront payment and up to $3.4 billion in potential milestones, and it is currently running two DAC programs. Additionally, Firefly Bio, which raised a $94 million Series A round, and Prelude Therapeutics (PRLD), focused on licensing CDK9 degrader payloads, have entered the space. These companies are engaging in intense competition to secure differentiated intellectual property from early stages by leveraging proprietary linker technologies and optimized payload degradation efficiency.

Challenges and Commercial Outlook for DAC Technology

For early‑stage DAC therapeutics to gain market traction, they must overcome formulation constraints such as payload stability and intracellular release efficiency. R&D is evolving toward smaller, more water‑soluble degrader payloads to enhance conjugation stability with the antibody. In the short term, anticancer DACs targeting validated tumor antigens will serve as the gateway for clinical data, while in the long term the market is expected to expand into unmet areas such as autoimmune diseases that require selective immune‑cell depletion. If successful, this innovative platform could destroy numerous disease‑causing proteins that are inaccessible to traditional small‑molecule inhibitors, fundamentally reshaping the global precision biotherapeutics market.